Source link : https://www.newshealth.biz/health-news/fda-oks-first-in-class-antipsychotic-for-schizophrenia/
The US Food and Drug Administration (FDA) has approved KarXT (Cobenfy; Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to dopamine receptors, which has been the standard of care for more than 30 years. It combines xanomeline, an oral muscarinic cholinergic receptor agonist and trospium chloride, an […]
Author : News Health
Publish date : 2024-09-27 14:22:19
Copyright for syndicated content belongs to the linked Source.
Categories